Chrono Therapeutics Announces Appointment of David Happel as Chief Executive Officer

February 1, 2018

Chrono Therapeutics, a pioneer in digital drug therapy, today announced that Alan Levy Ph.D., Chief Executive Officer (CEO) and Chairman of the Board of Directors is retiring. David A. Happel has been appointed as the new CEO and current Board member James Young will assume the role of Chairman of the Board. Dr. Levy will continue to serve as a member of the Board.

Chrono Therapeutics Raises $47.6 Million in Series B Financing to Advance its Clinical Platform for Personalized Drug Therapy

September 8, 2016

Chrono Therapeutics, a pioneer in digital drug therapy and recent recipient of the World Economic Forum Technology Pioneer Award, today announced that it has closed a $47.6 million Series B financing. The round was led by Kaiser Permanente Ventures and included investments by Endeavour Vision, Xeraya Capital Labuan Ltd, Asahi Kasei, Emergent Medical Partners, Hikma Ventures, Cota Capital, and Mission Bay Capital.

Chrono Therapeutics Receives ISO 13485 Certification

July 20, 2016

Chrono Therapeutics, a pioneer in digital drug therapy, announced today that its Hayward, California location has received ISO 13485 certification from accredited certification body DEKRA Certification B.V. This certification demonstrates Chrono’s commitment to establishing and following policies, practices and procedures to meet the customer, safety and regulatory requirements applicable to medical devices.

Chrono Therapeutics' Smoking Cessation Technology Demonstrates Significant Reduction in Nicotine Cravings

March 4, 2016

Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.

Chrono Therapeutics Receives Second Fast Track SBIR Grant from National Cancer Institute for Patient-Individualized Smoking Cessation Therapy

August 25, 2015

Chrono Therapeutics, a pioneer in digital drug therapy, today announced it has received a second Phase 1 and Phase 2 Fast Track Small Business Innovation Research (SBIR) grant award from the National Cancer Institute (NCI). This award of up to $2.3 million will support final product development of the digital portion of Chrono's patient-individualized smoking cessation therapy as well as pilot efficacy trials of the system.

Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStop™ Smoking Cessation Technology

March 3, 2015

Chrono Therapeutics, a pioneer in digital drug products, today announced an investment by Rock Health, the leading seed fund in digital health, to support the advancement of Chrono’s SmartStop™ programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation.

Chrono Therapeutics, Inventor of Wearable "Smart" Smoking Cessation Technology, Secures $32 Million in Series A Financing

June 12, 2014

Chrono Therapeutics, a pioneer in digital drug products, announced today the close of a $32 million Series A financing round, led by Canaan Partners and 5AM Ventures. Additional participants in the financing were Fountain Healthcare PartnersMayo Clinic and GE Ventures.

New Smoking Cessation Innovation Receives Grant from the National Institute of Health

February 10, 2014

The National Cancer Institute division of the NIH has recently awarded Chrono Therapeutics (CHRONO), a pioneer in digital drug products, a $2.23M grant to commercialize its lead product-SmartStop.™ Smartstop is the first “smart” transdermal nicotine replacement therapy (NRT) system that synchronizes the delivery of nicotine at the times of cravings to prevent cravings from occurring.